Northwestern Mutual Wealth Management Co. Has $1.42 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Northwestern Mutual Wealth Management Co. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 11.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,932 shares of the company’s stock after purchasing an additional 1,265 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Moderna were worth $1,417,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of MRNA. Vanguard Group Inc. boosted its holdings in Moderna by 22.6% in the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after acquiring an additional 6,248,623 shares in the last quarter. Wellington Management Group LLP grew its position in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Moderna by 42.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after purchasing an additional 463,960 shares in the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Moderna by 156.9% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock worth $79,044,000 after acquiring an additional 453,004 shares during the last quarter. Finally, Bellevue Group AG raised its stake in shares of Moderna by 27.6% in the fourth quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock worth $189,792,000 after purchasing an additional 413,095 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares of the company’s stock, valued at approximately $174,665,819.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the sale, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 78,158 shares of company stock worth $9,259,012 over the last quarter. Corporate insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and cut their price objective for the stock from $88.00 to $70.00 in a report on Friday, September 13th. Finally, Piper Sandler dropped their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Price Performance

Shares of Moderna stock opened at $60.20 on Friday. The company has a fifty day moving average of $78.45 and a 200-day moving average of $108.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna, Inc. has a 52-week low of $59.62 and a 52-week high of $170.47. The stock has a market capitalization of $23.07 billion, a price-to-earnings ratio of -3.84 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($3.62) EPS. Equities research analysts expect that Moderna, Inc. will post -9.86 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.